SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More
Seeking Alpha15:34 ET
Weekly Buzz: Magnificent Mix of Market Reactions
Kevin TraversNov 1 16:26 ET
November Starts with a Climb to end Tough Week | Wall Street Today
Kevin TraversNov 1 16:03 ET
Price Over Earnings Overview: AbbVie
BenzingaNov 1 12:15 ET
Friday Market Climbs on Amazon Earnings, Labor Numbers at Four-Year Low | Live Stock
Kevin TraversNov 1 10:52 ET
Alnylam Pharmaceuticals Analyst Ratings
BenzingaNov 1 06:05 ET · Ratings

Comments

股勇者

Oct 25 10:17

$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?

1

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

1

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

+1

CPI hits 3-year low: How will it sway the Fed rate decision?

15

3

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

5

1

Meltyy

Aug 6 02:51

$XBI down 3% today and 5% since before last Friday’s jobs report.

$SPDR S&P Biotech ETF (XBI.US)$
» Is this a smid-cap biopharma buying opportunity? 🤔
Stock market sell-off, e.g., $NASDAQ, started late last week on weak jobs data
XBI/smid-cap biopharma were part of sell-off
But..
» Is this sell-off justified for smid-cap biopharma?
» Is this a buying opportunity for smid-cap biopharma?
💡 Lower economic/jobs data = more likely entering lowering interest rate cycle for Fed Reserve
Usually go...

1

XBI SPDR S&P Biotech ETF

Trade Overview

Capital Trend

News

Comments